Supply's The Limit As Stevia-Based Sweeteners Gain In Popularity
This article was originally published in The Tan Sheet
Executive Summary
Stevia-based sweetener marketers appear to have cleared the challenge of FDA acceptance, but face another in ensuring ready availability of South American stevia rebaudiana
You may also be interested in...
Promoting Paraguayan stevia
The U.S. Agency for International Development and stevia extract manufacturer PureCircle encourage stevia cultivation in southern Paraguay through a cooperation and mutual investment agreement with the Paraguayan government. USAID's Paraguay Vende economic growth program will assist PureCircle South America in developing a business plan and stevia production basins in the Itapua department. "This is a very significant development" for the stevia industry, said PureCircle VP of Supply Chain Dorn Wenninger Oct. 12. PureCircle, with a U.S. office in Oak Brook, Ill., further cited the "enormous commercial opportunities and socioeconomic benefits that stevia cultivation is bringing to South America." As stevia-based sweeteners grow in popularity, stakeholders say limited supply is a problem (1"The Tan Sheet" July 6, 2009)
Wisdom stevia GRAS notice
FDA has no objections to Wisdom Natural Brands' affirmation that its stevia-based SweetLeaf Sweetener is generally recognized as safe, according to a letter the firm receives Sept. 1. Wisdom founder Jim May called FDA's validation "a tremendous victory" following research to prove the extract's safety and quality. Other firms including Blue California, Cargill and McNeil Nutritionals have received "no objection" notices from FDA regarding sweeteners made with the stevia preparation rebaudioside A (1"The Tan Sheet" July 6, 2009). SweetLeaf Sweetener was on the market for more than a year before Gilbert, Ariz.-based Wisdom received FDA's response to its GRAS affirmation
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle
Senate appropriators say FDA must decide how it will implement a provision of the FDA Amendments Act of 2007 that could substantially stifle innovation in the dietary supplement industry